Learn More

PrEP clinical guidelines

The 2019 ASHM PrEP Guidelines are now published online with a new website. These guidelines have been reviewed and updated by the PrEP guidelines panel and reviewed by the PrEP guidelines reviewing committee.The recommendations in these guidelines are designed to:

Support clinicians in prescribing PrEP using forms of coformulated tenofovir and emtricitabine that have been registered in Australia by the Therapeutic Goods Administration and other bioequivalent generic drugs that are available in Australia through self-importation, private prescription or Australian PrEP clinical trials

Please note these guidelines are a final version for interim use and are awaiting endorsement by the Blood Borne Viruses and Sexually Transmissible Infections Standing Committee